EyePoint Pharmaceuticals Appoints Esteemed Industry Leader Fred Hassan to Board of Directors
EyePoint Pharmaceuticals, Inc. (EYPT)
Last eyepoint pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors. “I am honored to welcome Fred Hassan to EyePoint’s Board,” said Göran Ando, M.D., Chair of the Board of Directors of EyePoint Pharmaceuticals. “He joins at an important time for the Company as we approach first patient dosing for the pivotal Phase 3 LUGANO trial of DURAVYU™ in wet age-related macular degeneration (AMD) and as we prepare for future commercialization. Fred is a visionary in the industry with extensive global biopharmaceutical experience, and his analytical and strategic insights will be invaluable as we continue to make progress in bringing a potential revolutionary treatment to patients.” “It is an honor to join the EyePoi
Show less
Read more
Impact Snapshot
Event Time:
EYPT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYPT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYPT alerts
High impacting EyePoint Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
EYPT
News
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at HC Wainwright from $30.00 to $22.00. They now have a "buy" rating on the stock.MarketBeat
- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target lowered by analysts at Robert W. Baird from $38.00 to $33.00. They now have an "outperform" rating on the stock.MarketBeat
- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) had its price target raised by analysts at Chardan Capital from $28.00 to $33.00. They now have a "buy" rating on the stock.MarketBeat
- EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
EYPT
Earnings
- 11/7/24 - Miss
EYPT
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/12/24 - Form SC
- EYPT's page on the SEC website